ACTG 219: PEDIATRIC LATE OUTCOMES PROTOCOL

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究正在寻找药物治疗对生长，发育，长期生存和生活质量的任何长期影响。 本研究的目的是随访正在或已经参加儿科ACTG研究的儿童和青少年。 这包括所有婴儿出生的人类免疫缺陷病毒（HIV）感染的母亲谁参加了一个ACTG药物研究时，他们怀孕，婴儿或儿童谁收到抗HIV疫苗，儿童和青少年参加长期生存者研究（LTS）由儿科艾滋病基金会赞助。 所有的孩子都将被跟踪到他们的21岁生日。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is looking for any long-term effects of drug therapy on growth, development, long-term survival, and quality of life. The purpose of this study is to follow children and teenagers who are or have been in pediatric ACTG research studies. This includes all babies born to human immunodeficiency virus (HIV) infected mothers who were enrolled in an ACTG drug study when they were pregnant, infants or children who received anti-HIV vaccines, and children and teenagers enrolled in the Long Term Survivors study (LTS) sponsored by the Pediatric AIDS Foundation. All children will be followed until their 21st birthday.